Table 3 Synthesis of cost-effectiveness analysis results and COMER outcomes
From: Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia
Category | References | Incremental costs(2023 US dollar) | Incremental effects | Total ICER(2023 US dollar) | NHB(2023 US dollar) | NHB < 0(%) | Weight (%) |
|---|---|---|---|---|---|---|---|
CS(QALY) | Kerr [24] | 4,702.79 | 0.48 | 49,630(37,223 to 62,038) | 19,648 | NHB > 0 | 0.4734 |
Ademi [40] | − 852.31 | 1.07 | 23,369 | NHB > 0 | 0.3346 | ||
Ademi [42] | 84,620.28 | 29.07 | 57,823 | NHB > 0 | 0.0547 | ||
Lázaro [31] | 39,591,894.47 | 767 | 547,516 | NHB > 0 | 0.0006 | ||
Ademi [32] | 31,369.18 | 2.53 | 36,563 | NHB > 0 | 0.1367 | ||
|  | \(\Sigma \omega *c\)=34,991 | \(\Sigma \omega *e\)=2.99 | TNHB = 25,614(19,210 to 32,017) | TNHB > 0 | \(\Sigma w\)=1 | ||
CS(LYG) | Ademi [40] | − 852.31 | 0.97 | 4,451(3,338 to 5,564) | 21,264 | NHB > 0 | 0.225 |
Ademi [42] | 84,620.28 | 24.95 | 37,634 | NHB > 0 | 0.0718 | ||
Oliva [34] | 8,922.69 | 1.34 | 17,108 | NHB > 0 | 0.3477 | ||
Wonderling [35] | 11,433.06 | 0.9 | 20,539 | NHB > 0 | 0.2412 | ||
Ademi [32] | 31,369.18 | 2.28 | 29,851 | NHB > 0 | 0.1142 | ||
|  | \(\Sigma \omega *c\)=15,331 | \(\Sigma \omega *e\)=2.95 | TNHB = 21,801(16,351 to 27,251) | TNHB > 0 | \(\Sigma w\)=1 | ||
CS (adverse events averted) | Kerr [24] | 4,702.79 | 104 | 406,03(30,452 to 50,753) | 5,271,321 | NHB > 0 | 0.0092 |
Ademi [40] | − 852.31 | 24.2 | 510,117 | NHB > 0 | 0.9795 | ||
Lázaro [31] | 39,591,894.47 | 847 | 4,734,156 | NHB > 0 | 0.0114 | ||
|  | \(\Sigma \omega *c\)=449,450 | \(\Sigma \omega *e\)=34.29 | TNHB = 601,825(451,368 to 752,281) | TNHB > 0 | \(\Sigma w\)=1 | ||
CS (deaths averted) | Kerr [24] | 4,702.79 | 16 | 179,369(134,526 to 224,211) | 806,993 | NHB > 0 | 0.0377 |
Marks [28] | 101,486,932.5 | 560 | − 64,766,053 | NHB < 0 | 0.000005 | ||
Ademi [40] | − 852.31 | 7.55 | 159,735 | NHB > 0 | 0.9633 | ||
Lázaro [31] | 39,591,894.47 | 203 | − 28,968,295 | NHB < 0 | 0.00003 | ||
|  | \(\Sigma \omega *c\)=1,110 | \(\Sigma \omega *e\)=7.88 | TNHB = 182,905(137,178 to 228,631) | TNHB > 0 | \(\Sigma w\)=1 | ||
US(QALY) | Marquina [30] | 1,061,544,599.77 | 51,790 | 20,860(15,645 to 26,075) | 854,219,290 | NHB > 0 | 0.00004 |
Spencer [19] | 20,836,899.42 | 97.5 | − 5,599,989 | NHB < 0 | 0.99996 | ||
|  | Σω*c = 20,881,624 | \(\Sigma \omega *e\)=99.72 | TNHB = − 5,563,039(− 6,953,798 to − 4,172,279) | TNHB < 0 | \(\Sigma w\)=1 | ||
US (deaths averted) | Marks [28] | 13,500,753.09 | 11.7 | 832,917(624,687 to 1,041,146) | − 12,733,549 | NHB < 0 | 0.99998 |
Marquina [30] | 1,061,544,599.77 | 1,279 | − 1,014,233,111 | NHB < 0 | 0.00002 | ||
|  | \(\Sigma \omega *c\)=13,665,924 | \(\Sigma \omega *e\)=11.9 | TNHB = − 12,891,385(− 16,114,231 to − 9,668,539) | TNHB < 0 | \(\Sigma w\)=1 | ||
US(LYG) | Marquina [30] | 1,061,544,599.77 | 33,488 | 32,262(24,197 to 40,328) | 177,210,008 | NHB > 0 | 0.004 |
Spencer [19] | 20,836,899.42 | 61.5 | − 11,225,925 | NHB < 0 | 0.996 | ||
|  | \(\Sigma \omega *c\)=24,996,554 | \(\Sigma \omega *e\)=195.1 | TNHB = − 10,472,757(− 13,090,946 to − 7,854,568) | TNHB < 0 | \(\Sigma w\)=1 |